Ikonisys completed a capital increase through
a private placement

Paris, November 19, 2024 – 8:00 am CEST - Ikonisys SA (Euronext Growth Paris: ALIKO), a company
specializing in the early and accurate detection of cancers through a unique, fully automated solution
for medical analysis laboratories (the “Issuer”), today announces that it has completed a capital
increase of €200k, by way of a private placement.

This operation is part of the ongoing series of recent capital increases aimed at strengthening the
Company's financial stability and diversifying its shareholder structure. The net proceeds from the
issuance, amounting to €200k, will contribute to financing the working capital.

Legal terms of the Capital Increase

The implementation of this capital increase, carried out with cancellation of shareholders' subscription
rights through a private placement, was approved by the Board of Directors of the Issuer at its meeting
held on November 12, 2024 (the "Capital Increase").

The new shares will be issued on the basis of the 16th resolution of the Issuer's shareholders' meeting
held on September 30, 2024. The settlement-delivery of the new shares will take place on November
19, 2024.

The Capital Increase did not require the approval of a notice (“prospectus”) by the Autorité des
marchés financiers (the “AMF”).

Main terms of the Capital Increase

The Issuer has issued a total of 130,720 new ordinary shares, with a par value of €0.5 each, to the
investor, pursuant to article L. 411-2 1° of the French Monetary and Financial Code, in accordance with
the 16th resolution passed by its Annual General Meeting on September 30, 2024.

The issuance price of the new shares issued under the Capital Increase, equal to €1.53 per share,
represents a premium of approximately 3% on the Ikonisys share price at the close of November 18,
2024.

Impact of the transaction in terms of liquidity risk management and financing horizon

As of December 31, 2023, and as mentioned in the annual financial report published on July 8, 2024,
the Issuer's consolidated cash position amounted to €9.4k.

In order to strengthen its financial resources, Ikonisys completed a capital increase of €1m on January
2, 2024 and more recently four capital increases for a total cumulative sum of €1m in June, July, August
and October 2024.




1/3
Taking into account these elements, the Capital Increase completed and the previously secured
financing facility, the Company considers that it is now in a position to meet its financing needs for
more than 12 months.

Impact of the Capital Increase on a shareholder holding 1% of the capital

On the basis of the 11,130,765 shares outstanding, the impact on the shareholding of a shareholder
holding 1% of the Issuer's capital prior to the transaction is as follows:

On a non-diluted On a diluted
basis basis1
Before completion of the Capital Increase 1.00% 0.82%
After issuance of the 130,720 shares resulting from the Capital
0.99% 0.81%
Increase
1 Dilutiontakes into account the exercise of all outstanding dilutive instruments likely to result in the issuance of a maximum
indicative number of 2,397,043 new shares (including the issuance of 2,000,000 for the closing of Hospitex International’s
acquisition).

Capital breakdown before and after completion of the Capital Increase

Before the Capital Increase:

Shareholder Number of shares % of share capital %of voting rights
Cambria Co-Investment
5,268,989 47.34% 54.64%
Fund
Cambria Equity Partners 1,974,049 17.74% 21.15%
MC Consulting* 351,464 3.16% 4.05%
Free float 3,536,263 31.77% 20.16%
Total 11,130,765 100% 100%
*Holding company of the CEO, Mario Crovetto



After the Capital Increase:

Shareholder Number of shares % of share capital %of voting rights
Cambria Co-Investment
5,268,989 46.79% 54.23%
Fund
Cambria Equity Partners 1,974,049 17.53% 20.99%
MC Consulting* 351,464 3.12% 4.02%
Free float 3,666,983 32.56% 20.76%
Total 11,261,485 100% 100%
*Holding company of the CEO, Mario Crovetto



Risk factors related to the Issuer

Detailed information about the Issuer, including its business, financial information, results, outlook
and related risk factors, is contained in the 2023 annual financial report for the financial year ended
December 31, 2023, published on July 8, 2024. This document, together with other regulated
information and all the Issuer's press releases, is available on the Issuer's website (www.ikonisys-
finance.com).




2/3
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated solutions designed to deliver accurate and reliable
detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic
applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy
platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor
Cells (CTC).
For further information, please go to www.ikonisys.com


Contacts
Ikonisys NewCap NewCap
Alessandro Mauri Louis-Victor Delouvrier/Aurélie Manavarere Nicolas Merigeau
CFO Investor Relations Media Relations
investors@ikonisys.com ikonisys@newcap.eu ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 94 Tel.: +33 (0)1 44 71 94 98



Disclaimer
This press release contains forward-looking statements about the Company's prospects and development. These statements
are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe",
"aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative
of these terms or any other similar variants or expressions. This information is not historical data and should not be construed
as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates
considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic,
financial, competitive and regulatory environment. This information contains data relating to the Company's intentions,
estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of
the Company. The forward-looking information contained in this press release is made only as of the date of this press
release. The Company does not undertake to update any forward-looking information contained in this press release, except
as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and
therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking
information constitutes a guarantee of actual results.




3/3